Compare CDMOs with neurology and CNS drug manufacturing experience for small molecules, biologics, and gene therapies targeting neurological conditions. Filter by modality, containment, and scale.
1 company listed
Neurology manufacturing spans a wide range of modalities: small molecule CNS drugs (antiepileptics, antidepressants, dopamine modulators), biologics (anti-amyloid antibodies for Alzheimer's, anti-CGRP for migraine), gene therapies (AAV vectors for spinal muscular atrophy, Parkinson's), and advanced delivery systems (intrathecal pumps, nasal sprays for CNS penetration).
Controlled substances are common in this space. Many neurological drugs -- benzodiazepines, opioid-based pain medications, stimulants for ADHD -- fall under DEA scheduling. CDMOs handling Schedule II-V compounds need DEA registration, vault storage, meticulous chain-of-custody documentation, and annual quota management. Not all CDMOs have this licensure.
Blood-brain barrier penetration drives formulation innovation. For drugs that struggle to cross the BBB, CDMOs with experience in nanoparticle formulations, lipid-based delivery systems, intranasal devices, or intrathecal formulations provide a competitive advantage. Gene therapy vectors for neurological targets (AAV9 for spinal cord, AAV-PHP.eB for brain) require specialized viral vector manufacturing capabilities.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.